14M111 Updated ACR Guidelines for Glucocorticoid-Induced Osteoporosis #ACR22 🦴🦴 Reminder: Recalculate FRAX scores with scaling for prednisone equivalent dosing! Use other clinical fracture risk assessments @RheumNow https://t.co/qZDlb1Cij7

Dr. B Humphrey #ACR22 #Osteoporosis Guidelines: FRAX needs to be adjusted according to the dose of GC's (7.5+ mg/day multiply FRAX score by 1.2) #ACR22 @rheumnow https://t.co/U7IOjbTwxN

#L01 #acr22 @rheumnow chronic GC use in rheum Dx assoctd w/⬇️ T scores & ⬆️fracture even if dose 2.5 mg or less. GC use ≥5 mg/day associated w/ 2-fold higher risk of fracture of any kind compared to all other doses& controls (aHR 2.37, 95% CI 1.33-4.23).Preventable w/anti-OP Rx https://t.co/sCWkEBPMMT

Almayali et al. Follow-up of GLORIA study. Now tapering of the pred 5mg after 2 years. Small increase in disease activity (to same level as prev placebo), numerical increase in flare. No adrenal insufficiency @RheumNow #ACR22 Abstr#2000 https://t.co/5oclSdlXWA https://t.co/HT2pmsxPiC

• Tapering of Long-term, Low Dose Glucocorticoids in Senior Rheumatoid Arthritis …

Wow! Walrabenstein et al. RCT of plant-based diet (and exercise and stress management) vs usual care in low-moderate disease activity RA. It worked! But which of the 3 parts of the intervention was responsible? @RheumNow #ACR22 Abstr#1998 https://t.co/X1f07ZWPjU https://t.co/nkM4misfFW

• Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical …

Yokose et al. Higher risk of mortality in women with gout. Primarily CVD related death. @RheumNow #ACR22 Abstr#1757 https://t.co/Ft3Km8Jw17 https://t.co/uBOUnV4n0Z

• The Independent Impact of Gout on Mortality and Risk of Coronary Heart Disease …

Haibel et al. Intraarticular morphine no different to placebo and inferior to steroid in knee OA. @RheumNow #ACR22 Abstr#1833 https://t.co/9dOlfYMVlj https://t.co/a3uvw3gVw3

• Intraarticular Morphine in Knee-arthritis – Results of a Randomized Placebo-con…

Kivitz et al. Phase 2 RCT Dazodalibep (non-antibody biologic antagonist of CD40L) in csDMARD/bDMARD-IR RA. Improve DAS28-CRP, CDAI, SDAI, TJC, SJC at day 113. @RheumNow #ACR22 Abstr#2008 https://t.co/RwRbeFC4rt https://t.co/F8bEI1lZGM

• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight an…

L09 #ACR22 MTX in Post-Roe Era 6% patients reported barrier to MTX access 1 pt noted restriction to HCQ Most delays due to pharmacy - told due to pregnancy/abortion concerns or unexplained reason Rare BUT Real Problem - shows importance of @ACRheumDC advocacy efforts @RheumNow https://t.co/8Yr7nynzN6

L10 #ACR22 Efgartigimod in IMNM IgG1 Fc fragment targeting neonatal Fc receptor (FcRn) Restored grip and muscle strength in mice studies with pathogenic anti-HMGCR+ (p<0.05) Total IgG and anti-HMGCR Ab became undetectable @RheumNow

Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-analysis of CARES trial. @RheumNow #ACR22 Abstr#1809 https://t.co/I6evAl4BLd https://t.co/n70FvYah1p

• Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients:…

Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, Rate ratio vs TNFi 2.2 (1.4-3.2). Age-adjusted HR 1.6 (1.0-2.6) @RheumNow #ACR22 Abstr#1752 https://t.co/PvBq2O9qPv https://t.co/XBfistBMhW

• Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic a…

Gurwith et al ABP-671 a URAT1 inhibitor effectively lowers serum urate @RheumNow #ACR22 Abstr#1822 https://t.co/hXAQoVHrLH https://t.co/saVqu4kbnr

• A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a…

L14 #ACR22 Bimekizumab BE MOBILE 1 and 2 Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nrAxSpA, 45% AS) to W52 (61%, 58%). Efficacy in TNF-naive & TNF-failure. AEs: Nasopharyngitis (12% nrAxSpA, 9% AS), URI (9, 6%), candidiasis (7, 6%), COVID (7, 2%) @RheumNow https://t.co/G31PrfqtVu